Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Home
Faculty
Departments
Grants
Publications
Prizes
Search by expertise, name or affiliation
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
ECHELON-2 Study Group
Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
507
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Brentuximab Vedotin
100%
Peripheral T-Cell Lymphoma
85%
Drug Therapy
36%
Vincristine
33%
Prednisone
32%
Cyclophosphamide
29%
Doxorubicin
28%
Progression-Free Survival
28%
Placebos
21%
Safety
18%
Anaplastic Large-Cell Lymphoma
14%
Febrile Neutropenia
13%
National Cancer Institute (U.S.)
12%
Peripheral Nervous System Diseases
10%
National Institutes of Health (U.S.)
10%
Random Allocation
10%
Pathology
6%
Survival
5%
Incidence
5%
Pharmaceutical Preparations
4%
Therapeutics
3%
Neoplasms
3%